Navigation Links
BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project
Date:9/12/2013

most of which are local providers at community-based facilities where 90 percent of cancer care and where clinical studies occur. These hospitals are enrolling cancer patients into the research project, and collecting the tissue samples to be sequenced and analyzed. By working through this community network, referral bias (influence of disparate data source) will be avoided since the patient population will be typical of the representative cancer patient in the community, as opposed to patients in tertiary cancer centers. This increases the ability to generate large enough data sets for analysis through predicative algorithms that could ultimately explain underlying biological causes of cancer.

In contrast to past research, where sample preservation was formaldehyde based for 30 years, hematology and oncology researchers involved in SA1kCGP have agreed to change the paradigm for genomic oncology by using fresh tissue for this analysis. The logistics of obtaining fresh tissue is a major hurdle to large scale genomic research in oncology, a barrier that START has addressed by targeting community treatment centers, where 90 percent of cancer care occurs. These samples will also be available for further research in areas of RNA and protein analysis to complement the DNA sequencing.


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. University of Minnesota startup offers game-changing energy solutions that reduce CO2 emissions
2. Starting a family does not encourage parents to eat healthier
3. Lets get moving: Unraveling how locomotion starts
4. Scientists start explaining Fat Bastards vicious cycle
5. NTU start-up launches worlds first 3-in-1 water monitoring system
6. Work starts on fossil fuel free cargo ship set to transform shipping industry
7. Large, medically important class of proteins starts to yield its secrets
8. New research association started: Magnesium implants shall facilitate bone fracture healing
9. To know a tiger is at least to start tolerating them, study shows
10. ERC starting grant for Friederike Range
11. Academia should fulfill social contract by supporting bioscience startups, case study says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Increasing adoption in ... to drive biometric systems market in ... According to a recently released TechSci Research ... biometric systems market in Saudi Arabia ... CAGR of over 22% through 2020. The market ...
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/14/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... York Design Awards under the category  ,Product Design – ... Awards are part of a global multi-disciplinary awards program. ... the marketplace, industry and judging panel. Winners will be ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... by eating the leaves of an invasive tree that soaks ... down water loss in the Southwestern United States. Two ... U.S. Geological Survey and the U.S. Department of Agriculture, have ... result from using Asian beetles for the biological control of ...
... WEST LAFAYETTE, Ind. - A Purdue University scientist and ... improved plant growth regulators that are expected to be ... of horticulture, said the growth inhibitors block the transport ... the plant, controls growth processes. Current growth regulators that ...
... whose work has overtones of Indiana Jones as they ... that could become the source of life-saving new medicines, ... international agreement on biodiversity will affect their work. That,s ... News (C&EN), ACS,s weekly newsmagazine. C&EN Associate ...
Cached Biology News:Scientists study control of invasive tree in western US 2Scientists study control of invasive tree in western US 3New growth inhibitors more effective in plants, less toxic to people 2
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... ROCKLAND, Mass. , April 16, 2015 /PRNewswire/ ... of Merck KGaA, Darmstadt, Germany ... Senior Vice President, Head of Global Clinical Development. ... development expertise, including experience in Oncology and Immunology. ... leadership ability, having served as a Vice President ...
(Date:4/16/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), ... cancer therapies in new orphan drug indications, today announced ... been added as a clinical trial site for the ... with refractory glioblastoma multiforme (GBM), the most common and ...
(Date:4/16/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ... personalized immune therapies for cancer, announced today that ... Immunotherapy Index (LCINDX), a professional index recently established ... within the biotechnology space.  The ... in the immunotherapy space, including 6 big pharma ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... Biopharmaceuticals (Nasdaq: KERX ) today announced completion ... its Phase 3 registration program of Zerenex™, the Company,s ... serum phosphorus levels, or hyperphosphatemia, in patients with end-stage ... registration program, which is being conducted pursuant to a ...
... NEW HAVEN, Conn., Sept. 19, 2011 The U.S. ... of allowance related to Cenestra Health,s high-purity omega-3 fatty ... claims cover a range of high-purity omega-3 formulations including ... Cenestra Health was issued U.S. Patent No. ...
... 16, 2011 Generex Biotechnology Corporation ( www.generex.com ... Napolii, from University Campus Bio-Medico in Rome, Italy, ... on Generex Oral-lyn™ buccal insulin spray on September ... Study of Diabetes (EASD) annual meeting in Lisbon, ...
Cached Biology Technology:Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 2Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 3Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study 4Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 2Cenestra Health Issued Notice of Allowance: Expands Patent Range of High-Purity Omega-3 Fatty Acid Formulations 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 2Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 3Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting 4
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
96 Well Base Plate...
... Inhibitor is a potent noncompetitive ... as RNase A. Like other ... Inhibitor is an acidic protein ... kDa. RNaseOUT inhibits RNase A ...
... Natural and Recombinant RNasin Ribonuclease Inhibitors have ... inhibition of eukaryotic RNases of the neutral ... inhibitory effect by noncovalently binding to RNases ... for the binding of RNasin Ribonuclease Inhibitor ...
Biology Products: